July 10, 2012

Media Contact: Sharon Likos


BIRMINGHAM, Ala. – The Alabama Center for Childhood Cancer and Blood Disorders was recently awarded the Hyundai Scholar Grant in support of pediatric cancer research. The $75,000 grant was presented to Stuart Cramer, D.O. and will support his research on understanding the mechanisms of chemotherapy drug resistance in children with neuroblastoma. The Alabama Center for Childhood Cancer and Blood Disorders was awarded one of 43 Hope On Wheels’ 2012 Hyundai Scholar Grants, which are given to principal investigators to support their research toward finding a cure and improving the quality of life for children with cancer.

The official presentation of the Hyundai Scholar Grant to Dr. Cramer took place on Wednesday, June 26 at Children’s of Alabama during a handprint ceremony. Pediatric cancer patients placed an array of colorful handprints on a new Hyundai Tucson to honor their struggle with the disease.

Dr. Cramer expressed his gratitude saying, “The Hyundai Hope on Wheels’ Scholar Grant will allow me the opportunity to continue to investigate the role drug resistant transporters play in neuroblastoma disease progression. I appreciate their support and vision of improving survival of difficult to treat pediatric malignancies. With their support, young investigators will have the opportunity to find a cure.”

The title of Dr. Cramer’s research is, “Resistance to MLN8237 in Neuroblastoma Xenografts is a Direct Result of Multidrug Resistance Transporters.” According to Dr. Cramer, neuroblastoma accounts for about 15% of cancer deaths in children and despite advancements and treatment the overall survival rate continues to be poor for patients with high risk diagnosis.

The Alabama Center for Childhood Cancer and Blood Disorders is a partnership between Children’s of Alabama and the UAB Division of Pediatric Hematology-Oncology. More than a dozen highly-specialized pediatric hematologists, oncologists and blood and marrow transplant physicians at Children’s provide care to infants through young adults up to age 25. A multidisciplinary team approach provides family-centered treatment and support through a variety of innovative services from the day of diagnosis through treatment, cure and long-term follow-up.